Figure 4
Checkpoint inhibition improves VSV-ASMEL therapy and uncovers a Th1 anti-tumour response. C57Bl/6 mice (7–8 per group) bearing 5-day established B16 tumours received six injections of either VSV-GFP or VSV-ASMEL on days 5, 7, 9, 12, 14, 16, followed by six injections of anti-PD-1 (250 μg) or control Ig on days 19, 21, 23, 26, 28, 30. (a) Tumour measurements were taken 3x per week and mice euthanised when tumours reached 1.0 cm diameter. Graph shown is representative of n=3 individual experiments, *P<0.05 log-rank test. (b, c) S/LN were harvested from four mice/group at time of sacrifice. Single cell suspension cultures of S/LN were re-stimulated with B16 F/T lysate every 24 h. Supernatants were harvested after 72 h and tested for IL-17 (b) and IFN-γ (c) by ELISA. Bars on graphs show values +s.d. (triplicate wells) for individual mice. **P<0.01, ***P<0.001 two-tailed t-test.
